Kymera Therapeutics (KYMR) Stifel 2026 Virtual Immunology and Inflammation Forum summary

Company overview and pipeline focus

• Focused on targeted protein degradation to remove disease-causing proteins, with a decade of optimization in target selection and molecule development.

• Pipeline includes a STAT6 degrader in phase II-B studies and an IRF5 program with phase I data to be shared soon.

• Partnerships with major pharma companies Sanofi and Gilead complement a wholly owned pipeline.

STAT6 degrader (KT-621) clinical development

• Phase II-B readout for KT-621 accelerated to end of 2026 due to high patient and investigator interest, strong early data, and global engagement.

• Enrollment speed attributed to demand for oral therapies and robust trial oversight, not at the expense of data quality.

• Adolescents included in phase II-B, reflecting both regulatory and commercial opportunity in pediatric type 2 diseases.

• Efficacy expectations are in line with leading biologics, with market analysis suggesting oral therapies need not match injectables to be commercially successful.

• Dose selection strategy aimed at identifying optimal phase III dose, with expectation that top two doses may show similar efficacy.

Safety and platform considerations

• No conjunctivitis observed in phase I-B, but larger studies needed to confirm safety profile.

• Long-term animal studies showed no adverse findings, supporting STAT6 specificity and safety.

• Anticipates safety profile similar to dupilumab, with ongoing studies to validate in larger patient populations.